PJC News Alert Piper Jaffray Companies (PJC) 55.10 02/14/2015

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Piper Jaffray Companies (PJC) 55.10 $PJC

Piper Jaffray Companies (PJC) Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Feb 05, 1:40PM CST

PJC: 55.10 (-1.61)

Piper Jaffray misses by $0.04, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Feb 05, 7:02AM CST

PJC: 55.10 (-1.61)

Piper Jaffray Companies Announces 2014 Fourth Quarter and Year-end Results
Business Wire - Thu Feb 05, 7:00AM CST
Piper Jaffray Companies (NYSE: PJC) today announced its financial results for the quarter and year ended December 31, 2014.
PJC: 55.10 (-1.61)

The SPDR S&P 600 Small Cap ETF: Let's Analyze It Using Our Scorecard System
Mycroft - at Seeking Alpha - Tue Jan 27, 6:54PM CST

CLMS: 12.96 (-0.08), IBKR: 32.51 (-0.04), SLY: 106.23 (+0.36), IO: 2.54 (+0.02), EIG: 21.58 (-0.15), PJC: 55.10 (-1.61), MOH: 59.66 (+0.26), TTWO: 28.40 (+0.96), AMSF: 43.70 (-0.18), ENVA: 22.30 (+0.35), AEL: 29.15 (+0.66), HCI: 50.01 (+0.71), WRLD: 78.79 (-0.21), UVE: 23.23 (-0.27), CSH: 20.53 (-0.31), OUTR: 68.39 (+2.22)

Piper Jaffray Companies to Hold Management Conference Call to Discuss 2014 Fourth Quarter and Year-End Results
Business Wire - Mon Jan 26, 12:59PM CST
Piper Jaffray (NYSE JC) announced today that it will release its 2014 fourth quarter and year-end results prior to the opening of the market on Thursday, February 5, 2015. The company will also hold a conference call to review the financial results at 9:00 a.m. ET (8:00 a.m. CT). Andrew S. Duff, chairman and chief executive officer, and Debbra L. Schoneman, chief financial officer, will host the call.
PJC: 55.10 (-1.61)

Upgrade Alert for Piper Jaffray (PJC)
Comtex SmarTrend(R) - Mon Jan 26, 8:05AM CST
Piper Jaffray (NYSE JC) was upgraded from Underperform to Neutral at Macquarie today. The stock closed yesterday at $53.18 on volume of 85,000 shares, below average daily volume of 137,000. Potential upside of 1.5% exists for Piper Jaffray, based on a current level of $53.18 and analysts' average consensus price target of $54.00. The stock should find resistance at its 50-day moving average (MA) of $56.68, as well as support at its 200-day MA of $51.57.
PJC: 55.10 (-1.61)

Cloud Computing: A 2-Horse Race Between Microsoft Corporation and Amazon.com, Inc.?
Tim Brugger, The Motley Fool - Motley Fool - Tue Jan 13, 8:01AM CST
Predicting the size and scope of cloud-related sales, let alone which of the industry leaders are truly leading the way from a revenue perspective can be frustratingly difficult. For example, research firm IDC a year ago suggested cloud revenues...
AMZN: 381.83 (+4.66), IBM: 160.40 (+1.88), PJC: 55.10 (-1.61), GOOGL: 551.16 (+5.15), MSFT: 43.87 (+0.78), GOOG: 549.01 (+6.08)

Apple, Inc.'s iPhone 6 Supply Continues to Improve
Daniel Sparks, The Motley Fool - Motley Fool - Tue Jan 06, 11:37AM CST
With more than enough demand for Apple 's newest iPhones during the company's fiscal first quarter, iPhone sales during the three months will be mostly dependent on how many iPhones it could produce -- a storyline that has played out again and...
PJC: 55.10 (-1.61), AAPL: 127.08 (+0.62)

Why XOMA Corp. Stock Plunged 37% in December
Sean Williams, The Motley Fool - Motley Fool - Mon Jan 05, 1:03PM CST
What: Shares of XOMA , a clinical-stage biopharmaceutical company focused on developing therapies to primarily treat metabolic, inflammatory, and infectious diseases, were absolutely decimated in December, losing 37% of their value, according to...
PJC: 55.10 (-1.61), XOMA: 3.41 (-0.01)

Apple, Inc. Television Rumors Are Back -- and Why You Should Ignore Them
Daniel Sparks, The Motley Fool - Motley Fool - Wed Dec 24, 7:00AM CST
Piper Jaffray analyst Gene Munster has been predicting for four years that Apple will launch its own television set. One of his most recent failed predictions for an Apple-branded television was that the company would launch one at the end of...
PJC: 55.10 (-1.61), AAPL: 127.08 (+0.62)

Matthew O'Brien Joins Piper Jaffray Medical Technology Investment Research Team
Business Wire - Tue Dec 23, 1:27PM CST
Piper Jaffray (NYSE JC) is pleased to announce the hiring of Matthew O'Brien as a principal and senior research analyst. O'Brien will be based in the firm's Chicago office, focused on the orthopaedics and spine space as part of the medical technology equity research team.
PJC: 55.10 (-1.61)

Stifel (SF) Announces Redemption of Senior Notes Due 2022 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 3:10PM CST
Stifel Financial Corp. (SF) recently announced the hundred percent redemption of its outstanding 6.7% Senior Notes due 2022. The principal amount of the notes, issued in Jan 2012, was $175 million.
SF: 51.76 (-0.16), PJC: 55.10 (-1.61), FXCM: 2.21 (-0.01), BGCP: 9.34 (+0.19)

Goldman Continues Foray into the ETF Market via New ETFs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 9:30AM CST
The Goldman Sachs Group, Inc. (GS) which jumped on the bandwagon of Wall Street banks which are targeting the fastest growing market of actively managed exchange-traded funds (ETFs) in September, has filed for a number of new alternative exchange-traded funds.
GS: 189.00 (-0.78), JPM: 59.67 (+0.10), PJC: 55.10 (-1.61), WFC: 55.33 (+0.47)

Broadcom Corporation in 2015: What Internet of Things Investors Need to Know
Chris Neiger, The Motley Fool - Motley Fool - Mon Dec 15, 4:28PM CST
Broadcom  is a strong competitor in the semiconductor business, but lately the company has been diving further into its Internet of Things, or IoT, ambitions. While investors should not expect huge revenue from Broadcom's IoT pursuits anytime soon,...
BRCM: 45.69 (+0.23), QCOM: 70.88 (+0.49), PJC: 55.10 (-1.61), IT: 81.53 (+1.64), INTC: 34.36 (+0.23), AAPL: 127.08 (+0.62), CSCO: 29.43 (-0.03)

Schwab Corporation's November Net New Assets Down 7% Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 10:20AM CST
The Charles Schwab Corporation (SCHW) recorded net new assets, bought by existing as well as new clients, of $10.9 billion for Nov 2014. This reflects a decrease of 7% from the prior-year month, but an increase of 38% from the preceding month.
PJC: 55.10 (-1.61), ETFC: 25.65 (-0.26), AMTD: 35.84 (-0.22), SCHW: 29.13 (-0.83)

E*TRADE Financial (ETFC) November DARTs Descend 7% Q/Q - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 9:20AM CST
Online brokerage firm, E*TRADE Financial Corporation (ETFC) reported a jump in its Daily Average Revenue Trades (DARTs) for Nov 2014. According to the monthly market activity report for November, E*TRADE's DARTs were 163,045, down 7% from the prior month while it remained unchanged on a year-over-year basis.
PJC: 55.10 (-1.61), ETFC: 25.65 (-0.26), FXCM: 2.21 (-0.01), AMTD: 35.84 (-0.22)

M&T Bank, Hudson City Merger Delayed for 3rd Time - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 4:41PM CST
The closing date of the proposed merger between M&T Bank Corporation (MTB) and Hudson City Bancorp, Inc. (HCBK) has been further extended to Apr 30, 2015 from the previous deadline of Dec 31, 2014.
PFBC: 28.02 (+0.28), PJC: 55.10 (-1.61), MTB: 123.90 (+0.52), HCBK: 9.92 (+0.03)

Morgan Stanley's Growth Unabated on Restructuring Plans - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 09, 10:00AM CST
Morgan Stanley continues to benefit from its restructuring initiatives as well as organic and inorganic expansion plans focusing mainly on less capital intensive operations.
GS: 189.00 (-0.78), PJC: 55.10 (-1.61), GCAP: 8.67 (+0.17), MS: 36.78 (-0.12)

Do Morgan Stanley's Low Deferrals Hint Financial Strength? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 08, 9:20AM CST
Morgan Stanley (MS) showcased its strengthening financial ability by bringing the employees' incentive compensation policy closer to the entire industry's long-term policy for the same.
GS: 189.00 (-0.78), EVR: 52.14 (+0.07), PJC: 55.10 (-1.61), MS: 36.78 (-0.12)

Interactive Brokers' November Metrics Down Sequentially - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 02, 5:40PM CST
Interactive Brokers (IBKR) recorded a sequential decrease in brokerage metrics for Nov 2014.
GS: 189.00 (-0.78), IBKR: 32.51 (-0.04), PJC: 55.10 (-1.61), FXCM: 2.21 (-0.01)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

TechCrunch Disrupt 2026: NYSE and Snowflake Highlights

Updated Category News Views 21

Ever noticed how the air vibrates just a bit more when major players like NYSE and Snowflake start shaking hands at big-league events like TechCrunch Disrupt? You'd better believe we're seeing a fresh brew of opportunities and challenges in the market as these titans lock horns and share insights. It's no small feat when the financial nerve center partners into the tech...

Continue Reading
Paradigm Therapeutics: A Beacon in Rare Diseases

Updated Category News Views 4

A Step Towards Recognition You know the old saying: innovation never sleeps. Well, Paradigm Therapeutics seems to have taken that to heart. The company's embarked on a peculiar yet promising journey with SD-101 (Zorblesia™), and here they are, basking in the glow of another nomination for the 2026 Prix Galien USA "Best Start-Up" award. It’s their second shot at this...

Continue Reading
Partner Valuation Advisors Bolsters Team with Eichman

Updated Category News Views 7

Eichman Joins Partner Valuation Advisors as MD Turns out the buzz in real estate appraisal isn’t just about property values these days; it's about who's valuing them. Just ask Partner Valuation Advisors, who are realigning their chess pieces by bringing seasoned pro Justin Eichman, MAI, on board as Managing Director. Talk about playing your cards right. A Heavyweight in...

Continue Reading
Skiptown Expands in Georgia Amid Growing Demand

Updated Category News Views 24

With the pet care industry barking up a storm lately, Skiptown is ramping up efforts to expand its presence in Georgia. The tech-enabled dog care franchise already has a paw print in Atlanta, but it's sniffing out new opportunities across the state. Now they're on the hunt for franchise owners who can bring this modern approach to more communities. Why Georgia? The Growth...

Continue Reading
Think Tank Pushes for Bold Parkinson's Prevention Plan

Updated Category News Views 25

A New Era for Parkinson's Disease Prevention The Parkinson's Foundation has rolled out its battle plan to take on Parkinson's disease from the ground up, shifting gears from managing symptoms to stopping the illness before it starts. It's about damn time, too. With the disease being the fastest-growing neurodegenerative disorder and impacting 10 million people worldwide,...

Continue Reading
Veterans Transitioning to Real Estate with Scholarships

Updated Category News Views 15

Tapping Military Skills for Civilian Gain Finding a new career after military service is a mountain of a task, but veterans now have a golden ticket into the real estate appraisal world. The Appraisal Institute's Next Mission Scholarship is throwing veterans a $1,000 life preserver to dive into a field where their military-honed skills already shine. The Power of a...

Continue Reading
Special Needs Group Partners with MAST to Enhance Accessibility

Updated Category News Views 22

Accessible Travel Takes the Spotlight Ah, the travel biz—just when you think you’ve got it all figured out, along comes a partnership like this to shake things up. Special Needs Group, the big cheese in mobility and medical equipment rentals, is teaming up with MAST Travel Network. Together, they're rolling out initiatives to make the world a bit more accessible, even...

Continue Reading
Omneky Outshines Competitors in AI Ad Scoring

Updated Category News Views 33

Brewing a better ad with AI isn't just about the model you plug in—it's about the wizardry wrapping around it. Omneky's latest caper in the AI advertising game has snagged the spotlight, pulling a hearty 8.8 taste score on a recent TasteBench comparison. That's not a minor tweak, folks, but a whopping 1.2-point lead over the shadow-chasing curves of the next...

Continue Reading
New Data on SKYRIZI Offers Hope for Crohn's Patients

Updated Category News Views 16

Treating Crohn's: New Hope on the Horizon Folks, let me tell you, the landscape for treating Crohn's disease just got a bit more interesting. AbbVie's Phase 3 AFFIRM study has brought some attention-grabbing data on the table, showcasing the potential of their drug, SKYRIZI® (risankizumab-rzaa). This ain't just another run-of-the-mill study; these results could be a...

Continue Reading
Honeywell Aerospace Faces Legal Turbulence in Fraud Case

Updated Category News Views 7

If you've got your chips on Honeywell Aerospace, Inc. (HONA), buckle up because things are getting choppy. Investors who took a bath on their shares now have the chance to put on their legal gloves and join a securities fraud class action lawsuit against the company. Legal Storm Over Misleading Statements Here's the rub: Between June 29 and September 1, 2026, the folks at...

Continue Reading

Top 5 Most Recently Viewed Articles

Pieridae Energy Limited Reports Strong Q3 2024 Performance

Updated Category News Views 58

Strong Financial and Operational Results from Pieridae Energy CALGARY, Alberta - Pieridae Energy Limited (“Pieridae” or the “Company”) (TSX: PEA) has announced its third quarter 2024 financial and operating results, showcasing an impressive production output and robust financial performance. The company achieved a production rate of 23,116 barrels of oil...

Continue Reading
Atea Pharmaceuticals Showcases Promising HCV Treatment Data

Updated Category News Views 136

Innovation in Hepatitis C Treatment by Atea Pharmaceuticals Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) has made a significant impact in the field of antiviral therapeutics through their ongoing research and development efforts. The company recently presented compelling data at The Liver Meeting 2024, highlighting the promising combination of bemnifosbuvir and ruzasvir for...

Continue Reading
Study Confirms Safety of Combined Eye Drops for Surgery Use

Updated Category News Views 172

Introduction to the Study A five-year pharmacovigilance study has confirmed the excellent safety profile of a fixed-dose combination eye drop developed by NTC. This eye drop combines an anti-inflammatory steroid and a quinolone antibiotic, designed for preventing and treating inflammation, as well as preventing infection after cataract surgery. Study Overview The findings...

Continue Reading
New Concerns Arise for Roblox Amid Allegations of Misreported Metrics

Updated Category News Views 203

Allegations Against Roblox: A Closer Look Roblox Corp (NYSE: RBLX) has recently come under fire after a report from Hindenburg Research highlighted potential discrepancies in its reported user metrics, leading to a notable decline in its stock prices. The gaming platform is being questioned for allegedly overstating its user metrics, including daily active users (DAUs)...

Continue Reading
uniQure N.V. Faces Investigation Amid Securities Fraud Concerns

Updated Category News Views 155

Understanding the uniQure N.V. Investigation Currently, uniQure N.V. is under investigation concerning possible violations of securities laws. This inquiry has raised significant concerns for shareholders and potential investors, driving many to seek assistance in understanding their rights moving forward. The investigation is being led by the DJS Law Group, an...

Continue Reading